157 related articles for article (PubMed ID: 26235945)
1. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY
Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945
[TBL] [Abstract][Full Text] [Related]
2. Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.
Song D; Lee M; Park CH; Ahn S; Yun CS; Lee CO; Kim HR; Hwang JY
Bioorg Med Chem Lett; 2016 Apr; 26(7):1720-5. PubMed ID: 26923695
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
4. Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.
Achary R; Mathi GR; Lee DH; Yun CS; Lee CO; Kim HR; Park CH; Kim P; Hwang JY
Bioorg Med Chem Lett; 2017 May; 27(10):2185-2191. PubMed ID: 28385505
[TBL] [Abstract][Full Text] [Related]
5. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment.
Park CH; Choe H; Jang IY; Kwon SY; Latif M; Lee HK; Lee HJ; Yang EH; Yun JI; Chae CH; Cho SY; Choi SU; Ha JD; Jung H; Kim HR; Kim P; Lee CO; Yun CS; Lee K
Bioorg Med Chem Lett; 2013 Nov; 23(22):6192-6. PubMed ID: 24095090
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
7. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
8. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH
Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
[TBL] [Abstract][Full Text] [Related]
10. Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.
Mesaros EF; Burke JP; Parrish JD; Dugan BJ; Anzalone AV; Angeles TS; Albom MS; Aimone LD; Quail MR; Wan W; Lu L; Huang Z; Ator MA; Ruggeri BA; Cheng M; Ott GR; Dorsey BD
Bioorg Med Chem Lett; 2011 Jan; 21(1):463-6. PubMed ID: 21074994
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.
Lu H; Tu W; Fei H; Xu G; Hu Q; Zhang L; Lin B; Yuan J; Yin J; Gong A; Wan M; Wang D; Zhu X; Feng J; Wang Q; Sun P
Bioorg Med Chem Lett; 2014 Jun; 24(11):2555-9. PubMed ID: 24755426
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Jin C; Meng X; Sun D; Xu X; Zhou Y; Liang Z; Ji M; Li H; Xu T; Song G; Zhang L; Chen G; Yuan H; Shih J; Zhang R; Hou G; Jin Y; Yang Q
Bioorg Med Chem Lett; 2015 Sep; 25(17):3738-43. PubMed ID: 26130408
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.
Achary R; Yun JI; Park CM; Mathi GR; Lee JY; Ha JD; Chae CH; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
Bioorg Med Chem; 2016 Jan; 24(2):207-19. PubMed ID: 26712094
[TBL] [Abstract][Full Text] [Related]
14. Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities.
Yun JI; Yang EH; Latif M; Lee HJ; Lee K; Yun CS; Park CH; Lee CO; Chae CH; Cho SY; Jung HJ; Kim P; Choi SU; Kim HR
Arch Pharm Res; 2014 Jul; 37(7):873-81. PubMed ID: 24129617
[TBL] [Abstract][Full Text] [Related]
15. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
[TBL] [Abstract][Full Text] [Related]
16. ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.
Lee HJ; Latif M; Choe H; Ali I; Lee HK; Yang EH; Yun JI; Chae CH; Jung JK; Kim HR; Lee CO; Park CH; Lee K
Arch Pharm Res; 2014; 37(9):1130-8. PubMed ID: 24446111
[TBL] [Abstract][Full Text] [Related]
17. Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Gingrich DE; Lisko JG; Curry MA; Cheng M; Quail M; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Haltiwanger RC; Wells-Knecht K; Ott GR; Ghose AK; Ator MA; Ruggeri B; Dorsey BD
J Med Chem; 2012 May; 55(10):4580-93. PubMed ID: 22564207
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
[TBL] [Abstract][Full Text] [Related]
19. Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Milkiewicz KL; Aimone LD; Albom MS; Angeles TS; Chang H; Grobelny JV; Husten J; Losardo C; Miknyoczki S; Murthy S; Rolon-Steele D; Underiner TL; Weinberg LR; Worrell CS; Zeigler KS; Dorsey BD
Bioorg Med Chem; 2011 Nov; 19(21):6274-84. PubMed ID: 21967808
[TBL] [Abstract][Full Text] [Related]
20. Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.
Weinberg LR; Albom MS; Angeles TS; Husten J; Lisko JG; McHugh RJ; Milkiewicz KL; Murthy S; Ott GR; Theroff JP; Tripathy R; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem Lett; 2011 Jan; 21(1):164-7. PubMed ID: 21123062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]